ReviewAAPS PharmSciTech2026
Next-Generation Bioinspired Microneedle Systems for Peptide Delivery: Bridging Design and Translational Medicine.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-based therapies have transformed the management of chronic illnesses such as diabetes, cancer, and cardiovascular problems, owing to their remarkable specificity, effectiveness, and low toxicity. Nonetheless, their therapeutic efficacy is frequently impeded by obstacles such as inadequate bioavailability, fast enzymatic breakdown, and restricted systemic stability. Conventional delivery strategies, such as oral and intravenous injection, have considerable constraints in efficiently transporting peptides to target locations. Transdermal drug delivery systems, especially microneedles (MNs) and bioinspired microneedles (BMNs), have garnered considerable interest as a less invasive and effective option to surmount these obstacles. MNs form microchannels in the epidermis and dermis, facilitating the direct administration of peptides into systemic circulation, hence dramatically improving peptide delivery across the skin. Recent improvements in BMNs technology have enhanced peptide delivery through better mechanical strength, skin contact, and controlled release. This paper mainly focuses on the importance of peptide drugs, the obstacles related to their administration, and the potential of BMNs for effective transdermal delivery. We emphasize current advancements in BMNs that improve peptide stability, permeability, and therapeutic effectiveness, facilitating their practical use in the treatment of chronic and acute disorders.
Indexed as
Identifiers
42946843What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.